WO2018018123A3 - Human anti-tetanus monoclonal antibodies neutralising infection by c. tetani, method for obtaining said monoclonal antibodies and use thereof in immunotherapy in the case of accidents with possible infection by tetanus bacillus - Google Patents
Human anti-tetanus monoclonal antibodies neutralising infection by c. tetani, method for obtaining said monoclonal antibodies and use thereof in immunotherapy in the case of accidents with possible infection by tetanus bacillus Download PDFInfo
- Publication number
- WO2018018123A3 WO2018018123A3 PCT/BR2017/050215 BR2017050215W WO2018018123A3 WO 2018018123 A3 WO2018018123 A3 WO 2018018123A3 BR 2017050215 W BR2017050215 W BR 2017050215W WO 2018018123 A3 WO2018018123 A3 WO 2018018123A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tetanus
- monoclonal antibodies
- infection
- immunotherapy
- tetani
- Prior art date
Links
- 208000015181 infectious disease Diseases 0.000 title abstract 4
- 230000002096 anti-tetanic effect Effects 0.000 title abstract 3
- 241000193449 Clostridium tetani Species 0.000 title abstract 2
- 206010043376 Tetanus Diseases 0.000 title abstract 2
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 241000193830 Bacillus <bacterium> Species 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 230000003472 neutralizing effect Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 238000010353 genetic engineering Methods 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000005259 peripheral blood Anatomy 0.000 abstract 1
- 239000011886 peripheral blood Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229960000814 tetanus toxoid Drugs 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The present invention relates to human anti-tetanus monoclonal antibodies against C. tetani infection, obtained by genetic engineering techniques using the information about the gene sequence obtained from B lymphocytes in the peripheral blood of persons vaccinated with tetanus toxoid. The genetic information is inserted into vectors used for transfecting mammal cells, with the aim of generating cell lines producing anti-tetanus monoclonal antibodies. Another aspect of the present invention relates to immunological compositions containing said monoclonal antibody, and to the uses thereof for the treatment and/or immunotherapy of tetanus infection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PH12019500431A PH12019500431A1 (en) | 2016-07-29 | 2019-02-27 | Neutralizing anti-tetanus human monoclonal antibodies for c. tetani infection, method of obtaining said monoclonal antibodies and their use in immunotherapy for accidents susceptible to tetanus bacillus infection |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR102016017782-0A BR102016017782A2 (en) | 2016-07-29 | 2016-07-29 | NUTRIENTING ANTITETANIC HUMAN MONOCLONAL ANTIBODIES FOR C.TETANI INFECTION, METHOD FOR OBTAINING MONOCLONAL ANTIBODIES AND THEIR USE IN IMMUNOTHERAPY FOR TETANIC BACILE INFECTION |
| BRBR1020160177820 | 2016-07-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2018018123A2 WO2018018123A2 (en) | 2018-02-01 |
| WO2018018123A3 true WO2018018123A3 (en) | 2018-03-22 |
Family
ID=59955306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/BR2017/050215 WO2018018123A2 (en) | 2016-07-29 | 2017-07-28 | Human anti-tetanus monoclonal antibodies neutralising infection by c. tetani, method for obtaining said monoclonal antibodies and use thereof in immunotherapy in the case of accidents with possible infection by tetanus bacillus |
Country Status (4)
| Country | Link |
|---|---|
| AR (3) | AR109221A1 (en) |
| BR (1) | BR102016017782A2 (en) |
| PH (1) | PH12019500431A1 (en) |
| WO (1) | WO2018018123A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110845609B (en) * | 2019-11-26 | 2021-06-15 | 武汉生物制品研究所有限责任公司 | Detection antibody pair aiming at tetanus toxoid and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0257195A (en) * | 1988-08-19 | 1990-02-26 | Morinaga & Co Ltd | Human type monoclonal antibody of anti-tetanus toxin |
| EP0562132A1 (en) * | 1992-03-23 | 1993-09-29 | SCHWEIZERISCHES SERUM- & IMPFINSTITUT BERN | Monoclonal anti-tetanus toxin antibodies and pharmaceutical compositions containing them |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1014570A (en) | 1996-07-05 | 1998-01-20 | Morihiro Matsuda | Antibody dna |
| CN102453091B (en) | 2010-10-20 | 2013-09-25 | 上海生物制品研究所有限责任公司 | Tetanus toxoid monoclonal antibody and preparation method and application thereof |
| CN105153305B (en) | 2015-06-26 | 2019-03-01 | 安泰吉（北京）生物技术有限公司 | A kind of full humanized anti-spasmotoxin monoclone antibody and its derivative preparation method and application |
-
2016
- 2016-07-29 BR BR102016017782-0A patent/BR102016017782A2/en active Search and Examination
-
2017
- 2017-07-28 WO PCT/BR2017/050215 patent/WO2018018123A2/en active Application Filing
- 2017-07-31 AR ARP170102180A patent/AR109221A1/en unknown
-
2019
- 2019-02-27 PH PH12019500431A patent/PH12019500431A1/en unknown
-
2022
- 2022-03-28 AR ARP220100737A patent/AR125232A2/en unknown
- 2022-03-28 AR ARP220100736A patent/AR125231A2/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0257195A (en) * | 1988-08-19 | 1990-02-26 | Morinaga & Co Ltd | Human type monoclonal antibody of anti-tetanus toxin |
| EP0562132A1 (en) * | 1992-03-23 | 1993-09-29 | SCHWEIZERISCHES SERUM- & IMPFINSTITUT BERN | Monoclonal anti-tetanus toxin antibodies and pharmaceutical compositions containing them |
Non-Patent Citations (2)
| Title |
|---|
| SMITH KENNETH ET AL: "Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen", NATURE PROTOCOLS, NATURE PUBLISHING GROUP, GB, vol. 4, no. 3, 1 January 2009 (2009-01-01), pages 372 - 384, XP009168769, ISSN: 1750-2799, DOI: 10.1038/NPROT.2009.3 * |
| THOMAS TILLER ED - MAJONE MAURO ET AL: "Single B cell antibody technologies", NEW BIOTECHNOLOGY, vol. 28, no. 5, 1 September 2011 (2011-09-01), pages 453 - 457, XP028290739, ISSN: 1871-6784, [retrieved on 20110405], DOI: 10.1016/J.NBT.2011.03.014 * |
Also Published As
| Publication number | Publication date |
|---|---|
| PH12019500431A1 (en) | 2019-10-28 |
| AR125232A2 (en) | 2023-06-28 |
| WO2018018123A2 (en) | 2018-02-01 |
| BR102016017782A2 (en) | 2018-02-14 |
| AR125231A2 (en) | 2023-06-28 |
| AR109221A1 (en) | 2018-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019283892A1 (en) | Anti-human papillomavirus 16 E7 T cell receptors | |
| MY173004A (en) | Mycobacterial antigen vaccine | |
| WO2012069568A3 (en) | Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination | |
| CR20220578A (en) | CD3-BINDING ANTIBODIES | |
| MY189819A (en) | Genetically modified cells and uses thereof | |
| WO2010104749A3 (en) | Antigen presenting cell targeted cancer vaccines | |
| WO2018185709A9 (en) | Compositions for reprogramming cells into dendritic cells or antigen presenting cells, methods and uses thereof | |
| BR112014011229A2 (en) | compositions and methods for the treatment of cytomegalovirus | |
| NZ599598A (en) | Hyperblebbing shigella strains | |
| GB2431582A (en) | Dendritic cell vaccines for treating cancer made from embryonic stem cells | |
| EP3792628A3 (en) | Methods for predicting the usefulness of neoantigens for immunotherapy | |
| WO2015112749A3 (en) | Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy | |
| WO2009114085A3 (en) | Allogeneic cancer cell-based immunotherapy | |
| WO2002074345A3 (en) | Immune modulation by transduced hematopoietic stem cells expressing antigens and antigen-presenting cell regulatory molecules | |
| WO2017203370A3 (en) | Cmv epitopes | |
| Nguyen et al. | Understanding CD8+ T‐cell responses toward the native and alternate HLA‐A∗ 02: 01‐restricted WT1 epitope | |
| WO2018018123A3 (en) | Human anti-tetanus monoclonal antibodies neutralising infection by c. tetani, method for obtaining said monoclonal antibodies and use thereof in immunotherapy in the case of accidents with possible infection by tetanus bacillus | |
| EA200701130A1 (en) | ELECTROPORATION OF MYCOBACTERIA AND SUPEREXPRESSION OF MYCOBACTERIA ANTIGENS | |
| WO2009042538A3 (en) | Immunogenic proteins from genome-derived outer membrane of leptospira and compositions and methods based thereon | |
| ATE494377T1 (en) | VACCINES AGAINST IPNV THAT ARE ISOLATED FROM Yeast CELLS | |
| WO2008127450A3 (en) | Linear expression cassette vaccines | |
| YU22202A (en) | Vaccina | |
| WO2006138449A3 (en) | Method for identifying a mhc class ii-dependent tumor-associated t helper cell antigen | |
| RU2012111811A (en) | PROTEINS USED FOR DIAGNOSTIC OF LIME BORRELIOSIS | |
| US11753624B2 (en) | Methods for generating functional therapeutic B cells ex-vivo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17771975 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 17771975 Country of ref document: EP Kind code of ref document: A2 |